Search - tctmd.com

Displaying 641 - 660 of 892

Sort: Relevancy | Date

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

March 09, 2017

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

News Daily News

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Yael L. Maxwell

March 03, 2017

Ticagrelor May Be Useful for Secondary Prevention After Stroke, TIA If Initial Event Is Related to Atherosclerosis

News Conference News ISC 2017

Ticagrelor May Be Useful After Stroke, TIA if Event Related to Atherosclerosis

February 28, 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

News Conference News ISC 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

February 24, 2017

Triple Antiplatelet Therapy Does Not Reduce Recurrent Events in Patients With Acute Ischemic Stroke or TIA

News Conference News ISC 2017

Triple Antiplatelet Therapy Does Not Cut New Events in Acute Ischemic Stroke or TIA

February 23, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

10-Year Follow Up of Early DES Shows Steady Risk of Late Events

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

February 08, 2017

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

Be It Resolved: E-Cigarettes May Help Smokers Cut Back, but Quit Altogether? The Jury’s Out

News Features

Be It Resolved: E-Cigarettes May Help Smokers Cut Back, but Quit Altogether? The Jury’s Out

January 20, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Features

Be It Resolved: As Evidence Mounts in Favor of a Brain-Heart Connection, Stress Should Be on the Radar During CVD Diagnosis

Yael L. Maxwell

January 16, 2017

News Features

Be It Resolved: Lifestyle Changes for Patients Needing Cardiac Rehab May Be a Life or Death Matter

Michael O'Riordan

January 10, 2017

News Features

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

January 04, 2017

News Daily News

AHA/ACC Report Recommends 10 Measures to Prevent Sudden Cardiac Death

December 23, 2016

News Daily News

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Michael O'Riordan

December 09, 2016

News Conference News AHA 2016

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

November 13, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

November 13, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.